º¹¸·Åõ¼®È¯ÀÚ¿¡¼­ º¹°­ ³» Ä®½ÃÆ®¸®¿Ã Ãæ°Ý¿ä¹ýÀÇ ºÎ°©»ó¼± È£¸£¸ó ¾ïÁ¦È¿°ú
The Effect of Intraperitoneal Calcitriol Pulse Therapy in CAPD Patients with Secondary Hyperparathyroidism

´ëÇѽÅÀåÇÐȸÁö 2008³â 27±Ç 6È£ p.707 ~ p.711

¼Ûȣö(Song Ho-Cheol) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
À¯¼±È«(Yoo Sun-Hong) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Á¤ÇöÈ­(Chung Hyun-Wha) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è¿ë±Õ(Kim Yong-Kyun) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
½Å¼®ÁØ(Shin Seok-Joon) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±èº´¼ö(Kim Byung-Soo) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è¿µ¿Á(Kim Young-Ok) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è¿ë¼ö(Kim Yong-Soo) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÃÖÀÇÁø(Choi Euy-Jin) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç

Abstract

¸ñ Àû: Åõ¼®ÁßÀÎ ¸»±â½ÅºÎÀü ȯÀÚ¿¡¼­ ½Å¼º °ñÀ̾çÁõÀº Áß¿ä ÇÕº´Áß¿¡ ÇϳªÀ̸ç ÀÌÀÇ Ä¡·á¸¦ À§ÇØ Ä®½ÃÆ®¸®¿ÃÀÌ ÁÖ·Î »ç¿ëµÇ°í ÀÖ´Ù. Ç÷¾×Åõ¼®ÀÇ °æ¿ì Ä®½ÃÆ®¸®¿Ã Á¤ÁÖ¿ä¹ýÀÌ ¸¹ÀÌ ¿¬±¸µÇ°í ÀÓ»ó¿¡¼­ »ç¿ëµÇ°í ÀÖÀ¸³ª º¹¸·Åõ¼® ȯÀÚÀÇ °æ¿ì Á¤ÁÖ¿ä¹ýÀÇ ÇÑ°è·Î ÀÎÇÏ¿© Á¤ÁÖ¿ä¹ý º¸´Ù´Â °æ±¸¿ä¹ý°ú º¹°­ ³» ÁÖÀÔÀÌ ÀÓ»ó¿¡¼­ ½Ãµµ µÇ°í ÀÖ´Ù. ƯÈ÷ º¹°­ ³» ÁÖ»çÀÇ °æ¿ì °æ±¸¿ä¹ýÀÇ ´ë¾ÈÀ¸·Î Á¦½ÃµÇ°í ÀÖÀ¸³ª ¾ÆÁ÷ ÀÌ¿¡ ´ëÇÑ Ä¡·á¹æ¹ýÀÌ È®¸³µÇÁö ¾ÊÀº ½ÇÁ¤ÀÌ´Ù. ÀÌ¿¡ º» ¿¬±¸¿¡¼­´Â º¹¸·Åõ¼®ÁßÀΠȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÏ¿© º¹°­ ³» Ä®½ÃÆ®¸®¿Ã Ãæ°Ý¿ä¹ýÀÇ È¿°ú¿Í ºÎÀÛ¿ëÀÇ ¹ß»ýºóµµ¸¦ ¾Ë¾Æº¸°íÀÚ ÀÌ ¿¬±¸¸¦ ½ÃÇàÇÏ¿´´Ù.

¹æ ¹ý: 2006³â 1¿ùºÎÅÍ 2007³â 1¿ù±îÁö °¡Å縯´ëÇб³ ¼º°¡º´¿ø¿¡¼­ 6°³¿ù ÀÌ»ó ¾ÈÁ¤ÀûÀ¸·Î º¹¸·Åõ¼®ÁßÀÌ¸ç ¿¬±¸¿¡ µ¿ÀÇÇÑ ÀÚ¸¦ ´ë»óÀ¸·Î ÇÏ¿´°í, iPTHÀÇ ÃøÁ¤Ä¡°¡ 300 pg/mL ÀÌ»óÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ¿¬±¸¸¦ ÁøÇàÇÏ¿´´Ù. ´ë»óȯÀÚ´Â Çѹø¿¡ 2 ¥ìg¾¿ ÁÖ 2ȸ º¹°­³»·Î Ä®½ÃÆ®¸®¿ÃÀ» Åõ¿©ÇÏ¿´´Ù. ¿¬±¸±â°£ Áß °íÄ®½·Ç÷Áõ (>10.5 mg/dL)°ú °íÀλêÇ÷Áõ (>6.5mg/dL)ÀÇ ¹ß»ý½Ã ¿¬±¸¿¡¼­ Á¦¿ÜÇÏ¿´´Ù.

°á °ú: ´ë»óȯÀÚ 18¸íÁß, º¹¸·¿°°ú °íÀλêÇ÷ÁõÀ¸·Î °¢°¢ 1¸íÀÌ ¿¬±¸¿¡¼­ Á¦¿ÜµÇ¾ú´Ù. ´ë»óȯÀÚÀÇ ¿øÀÎÁúȯÀº ´ç´¢º´¼º
½ÅÁõ, »ç±¸Ã¼½Å¿°, °íÇ÷¾ÐÁõ ½ÅÁõÀ̾ú´Ù. 3°³¿ù°£ÀÇ º¹°­³»Ä®½ÃÆ®¸®¿ÃÁÖÀÔ ÈÄ iPTHÃøÁ¤Ä¡°¡ Åõ¿© Àü (490¡¾234 pg/mL)¿¡ ºñÇØ 3°³¿ù Åõ¿© ÈÄ (318¡¾315 pg/mL) ÀÇ¹Ì ÀÖ°Ô °¨¼ÒÇÏ¿´´Ù (p<0.05). 3°³¿ù µ¿¾ÈÀÇ º¹°­ ³» Åõ¿©±â°£ Áß °íÄ®½·Ç÷ÁõÀº ¹ß»ýÀº ¾ø¾úÀ¸¸ç, 1¸í¿¡¼­ °íÀλêÇ÷ÁõÀÇ ¹ß»ýÀ¸·Î ¿¬±¸¿¡¼­ Á¦¿ÜµÇ¾ú´Ù. Åõ¿© ÈÄ 30% ¹Ì¸¸À¸·Î iPTH°¡ °¨¼ÒÇÑ ±ºÀÌ 30% ÀÌ»ó °¨¼ÒÇÑ ±º¿¡ (¹ÝÀÀ±º¿¡) ºñÇØ Åõ¿© Àü iPTH°¡ À¯ÀÇÇÏ°Ô ³ô¾Ò´Ù (p<0.05).

°á ·Ð: º¹¸·Åõ¼® ȯÀÚ¿¡¼­ ¹ß»ýÇÑ ÀÌÂ÷¼º ºÎ°©»ó¼±ÀÇ Ä¡·á¿¡ º¹°­ ³» Ä®½ÃÆ®¸®¿Ã Ãæ°Ý¿ä¹ýÀº ºñ±³Àû ³·Àº ºÎÀÛ¿ëÀÇ ºóµµ·Î Ä¡·áÇÒ ¼ö ÀÖ´Â ¼ö´ÜÀ̸ç È®¸³µÈ Ä¡·á¹æ¹ýÀ» À§ÇØ º¸´Ù ¸¹Àº ÀüÇâÀû ¿¬±¸°¡ ÇÊ¿äÇϸ®¶ó »ç·áµÈ´Ù.
Purpose: In hemodialysis patients with secondary hyperparathyroidism, intravenous administration of calcitriol became widely utilized. In CAPD patients, however, the intravenous administration of calcitriol is not practical. The purpose of the present study was to determine the effect and safety of intraperitoneal (IP) calcitriol pulse therapy in CAPD patients.

Methods: All patients undergoing CAPD between January 2006 and January 2007 and willing to give informed consent were eligible. Inclusion criteria were age greater 18 years, on CAPD for at least 6 months, and secondary hyperparathyroidism (intact PTH >300 pg/mL). Intraperitoneal calcitriol was given by direct infusion into the dialysate (2.0 ¥ìg) twice per week. If hypercalcemia (>10.5 mg/dL) and hyperphosphatemia (>6.5 mg/dL) developed, the patients were excluded from study.

Results: Eighteen patients were enrolled into the study. Among them, 16 patients completed the study period. After IP calcitriol for 3 months, there was a significant drop of iPTH level from the pretreatment level of 490¡¾234 pg/mL to the level of 318¡¾315 pg/mL (p<0.05). There were no definite hypercalcemia during the study period, and only 1 patient was excluded from study due to hyperphosphatemia.

Conclusion: In CAPD patients, IP calcitriol pulse therapy is effective in treating secondary hyperparathyroidism,
and that IP calcitriol pulse therapy is associated with a low incidence of hypercalcemia and hyperphosphatemia.

Å°¿öµå

Calcitriol, Injections, Intraperitoneal, Peritoneal Dialysis
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
IP calcitriol pulse therapy is effective in treating secondary hyperparathyroidism,
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå